Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B
Journal of Viral Hepatitis · 2024-04 · 31 (4) · 197-207
DOI: 10.1111/jvh.13918 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 19.01.2024. Verfasst von Mina S Farag und 15 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
We studied whether 48 weeks of PEG‐IFN alfa‐2a add‐on increases HBsAg‐decline and clearance in HBeAg‐negative patients on long‐term nucleo(s)tide analogue (NA) therapy. In this investigator‐initiated, randomized, controlled trial conducted in Europe and Canada, HBeAg‐negative patients treated with NA > 12 months, with HBVDNA < 200 IU/mL, were enrolled. Patients were randomized 2:1 to 48 weeks of PEG‐IFN alfa‐2a add‐on (180 μg per week) or continued NA‐monotherapy with subsequent follow‐up to Week 72. Endpoints were HBsAg decline (≥1 log 10 IU/mL) and HBsAg clearance at Week 48. Of the 86 patients in the modified‐intention‐to‐treat analysis, 58 patients received PEG‐IFN add‐on, and 28 continued NA monotherapy. At Week 48, 16(28%) patients achieved HBsAg decline ≥1 log 10 in the add‐on arm versus none on NA‐monotherapy ( p < .001), and HBsAg clearance was observed in 6 (10%) PEG‐IFN add‐on patients versus 0% NA‐monotherapy ( p = .01). HBVRNA was only detected in 2% after PEG‐IFN treatment versus 19% in NA‐monotherapy ( p = .002) at Week 48. PEG‐IFN add‐on therapy was well tolerated in majority of patients. Low baseline HBsAg levels ( 200 IU/mL at on‐treatment Week 12 was highly predictive of non‐response (NPV = 100%). Addition of PEG‐IFN to long‐term NA enhanced HBsAg decline and increased the chance of HBsAg clearance in HBeAg‐negative patients on long‐term NA. On‐treatment HBsAg levels >200 IU/mL identify patients unlikely to benefit from PEG‐IFN add‐on and could be used as a potential stopping‐rule for PEG‐IFN therapy. Our findings support further exploration of immune modulation add‐on to antiviral therapy, preferably using response‐guided strategies, to increase functional cure rates in patients with CHB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
- Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Gastroenterology, University Medical Center, Utrecht, The Netherlands.
- Department of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft, The Netherlands.
- Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Mina S Farag, Margo J H van Campenhout, M J Sonneveld, Kin Seng Liem, André Boonstra
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Farag, M. S., van Campenhout, M. J. H., Sonneveld, M. J., Fung, S., van Erpecum, K. J., Wong, D. K., Verhey, E., de Man, R., De Knegt, R. J., Brouwer, J. T., Baak, H. C., Feld, J. J., Liem, K. S., Boonstra, A., Hansen, B. E., & Janssen, H. L. A. (2024). Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B. Journal of Viral Hepatitis, 31(4), 197-207. https://doi.org/10.1111/jvh.13918
Vancouver
Farag MS, van Campenhout MJH, Sonneveld MJ, Fung S, van Erpecum KJ, Wong DK, et al. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B. Journal of Viral Hepatitis. 2024;31(4):197-207. doi:10.1111/jvh.13918
BibTeX
@article{Farag2024,
author = {Farag, Mina S and van Campenhout, Margo J H and Sonneveld, M J and Fung, Scott and van Erpecum, Karel J and Wong, David K and Verhey, Elke and de Man, Robert and De Knegt, Robert J and Brouwer, Johannes T and Baak, Hubertus C and Feld, Jordan J and Liem, Kin Seng and Boonstra, André and Hansen, Bettina E and Janssen, Harry L A},
title = {Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B},
journal = {Journal of Viral Hepatitis},
year = {2024},
volume = {31},
number = {4},
pages = {197--207},
doi = {10.1111/jvh.13918}
}
EUVIMED